{
  "ticker": "CMB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974489",
  "id": "02974489",
  "pages": 5,
  "price_sensitive": false,
  "date": "20250730",
  "time": "1114",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250730/pdf/06m9sw46gkdhzs.pdf",
  "summary": "### Capital Raising Announcement Summary:  \n- **Structure**: Placement  \n- **Total Securities Issued**: 4,570,667 shares (Ordinary Fully Paid, ASX: CMB)  \n  - **Under 15% capacity (ASX LR 7.1)**: 2,627,451 shares  \n  - **Under additional 10% capacity (ASX LR 7.1A)**: 1,828,266 shares  \n  - **Director Participation**: 114,950 shares (subject to shareholder approval at AGM Nov-2025).  \n- **Issue Price**: AUD 0.46370 per share.  \n- **Key Dates**:  \n  - **Initial Issue Date**: 28 August 2025 (for 4,455,717 shares).  \n  - **Director Shares Issue**: Within 1 month post-AGM (expected by late Nov-2025).  \n- **Use of Proceeds**: Phase 3 trials for Elate Ocular\u00ae + working capital.  \n- **Other**: No underwriting, no escrow, no dividend policy change.  \n\n**Note**: Majority issued under placement capacity (no SPP/entitlement offer). Secondary sale compliance via cleansing notice.",
  "usage": {
    "prompt_tokens": 1856,
    "completion_tokens": 256,
    "total_tokens": 2112,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-30T01:47:13.009811"
}